Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
11:32:04 EDT Sun 11 Oct 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

News for U:BMRN from 2025-10-10 to 2026-10-09 - 38 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2026-10-09 09:05U:BMRNNews ReleaseBioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting
2026-10-05 16:05U:BMRNNews ReleaseBioMarin Appoints Cara Bauer as Chief People Officer
2026-10-02 11:00U:BMRNNews ReleaseBioMarin Announces Five-Year Phase 3 Data for POMBILITI(TM) (cipaglucosidase alfa-atga) + OPFOLDA(TM) (miglustat) at World Muscle Society Annual Congress
2026-09-14 09:05U:BMRNNews ReleaseBioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors
2026-09-09 09:05U:BMRNNews ReleaseBioMarin Announces Positive Results of Phase 3 VOXZOGO(TM) (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence
2026-09-02 09:00U:BMRNNews ReleaseBioMarin to Participate in Upcoming Investor Conferences
2026-09-01 09:05U:BMRNNews ReleaseBioMarin Announces Close of the Alesta Therapeutics Acquisition
2026-08-31 02:00U:BMRNNews ReleaseBioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea
2026-08-18 08:30U:BMRNNews ReleaseBioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline
2026-08-10 09:05U:BMRNNews ReleaseBioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston
2026-08-06 16:03U:BMRNNews ReleaseBioMarin Reports Second Quarter 2026 Financial and Operating Results
2026-07-30 09:00U:BMRNNews ReleaseBioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET
2026-07-27 09:05U:BMRNNews ReleaseBioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome
2026-07-13 09:05U:BMRNNews ReleaseU.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO(TM) (vosoritide) for Children With Achondroplasia
2026-06-16 09:05U:BMRNNews ReleaseBioMarin Announces New Three-Year VOXZOGO(TM) (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026
2026-05-20 16:20U:BMRNNews ReleaseBioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO(TM) (vosoritide) in Children with Hypochondroplasia
2026-05-18 09:05U:BMRNNews ReleaseBioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency
2026-05-04 16:05U:BMRNNews ReleaseBioMarin Reports First Quarter 2026 Financial and Operating Results
2026-05-02 15:30U:BMRNNews ReleaseBioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO(TM) (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting
2026-04-27 08:44U:BMRNNews ReleaseBioMarin Completes Acquisition of Amicus Therapeutics
2026-04-27 07:30U:BMRNNews ReleaseBioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET
2026-04-21 16:23U:BMRNNews ReleaseBioMarin Announces Board Leadership Transition
2026-03-12 09:05U:BMRNNews ReleaseBioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO(TM) (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetic
2026-02-27 20:00U:BMRNNews ReleaseU.S. Food and Drug Administration Approves BioMarin's PALYNZIQ(TM) (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)
2026-02-24 09:00U:BMRNNews ReleaseBioMarin to Participate in Four Upcoming Investor Conferences in March
2026-02-23 16:05U:BMRNNews ReleaseBioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results
2026-02-17 09:00U:BMRNNews ReleaseBioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET
2026-02-12 16:05U:BMRNNews ReleaseBioMarin Announces Closing of Private Offering of Senior Notes
2026-01-29 16:05U:BMRNNews ReleaseBioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility
2026-01-26 07:45U:BMRNNews ReleaseBioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility
2026-01-12 16:05U:BMRNNews ReleaseBioMarin Appoints Arpit Dave Chief Digital and Information Officer
2026-01-08 16:05U:BMRNNews ReleaseBioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA
2026-01-08 08:30U:BMRNNews ReleaseVeeva and BioMarin Form Long-Term Strategic Partnership
2025-12-19 07:45U:BMRNNews ReleaseBioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
2025-11-11 09:00U:BMRNNews ReleaseBioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England
2025-10-29 09:00U:BMRNNews ReleaseFDA Accepts BioMarin's PALYNZIQ(TM) (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria
2025-10-27 16:03U:BMRNNews ReleaseBioMarin Reports Third Quarter 2025 Results and Provides Corporate Update
2025-10-22 16:05U:BMRNNews ReleaseBioMarin to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Monday, October 27, 2025, at 4:30pm ET